Beside preclinical evidence of its potential cardioprotective properties, and the clinical evidence of IL‐1 and IL‐6 inhibition against cardiovascular risk,135 direct clinical evidence of NLRP3 inhibition in protecting against HF or CVD is still lacking. This evidence concerns the gene NLRP3 and hydrops fetalis.